Literatur

  1. Cohen AT et al.: Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98(4): 756-64
  2. Van Es N et al.: Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124(12): 1968-75
  3. Agnelli G et al.: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369(9): 799-808
  4. Büller HR et al.: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366(14): 1287-97
  5. Castellucci LA et al.: Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 2014; 312(11): 1122-35
  6. Kearon C et al.: Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52
  7. Kyrle PA et al.: The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350(25): 2558-63
  8. Becattini C et al.: Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366(21): 1959-67
  9. Brighton TA et al.: Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367(21): 1979-87
  10. Weitz JI et al.: Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376(13): 1211-22
  11. Agnelli G et al.: Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368(8): 699-708
  12. Hohnloser SH et al.: Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33(22): 2821-30
Pfad: